Australia markets closed

Cellectis S.A. (CMVLF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
2.9600+0.3600 (+13.85%)
At close: 12:23PM EDT

Cellectis S.A.

8, rue de la Croix Jarry
Paris 75013
France
33 1 81 69 16 00
https://www.cellectis.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees216

Key executives

NameTitlePayExercisedYear born
Dr. Andre Choulika Ph.D.Co-Founder, CEO & Director876.6kN/A1965
Dr. David j. d. Sourdive Ph.D.Deputy CEO, Executive VP of CMC & Manufacturing and Director557.84kN/A1967
Mr. Arthur StrilInterim Chief Financial OfficerN/AN/A1989
Valerie CrosPrincipal Financial Officer & Principal Accounting OfficerN/AN/AN/A
Mr. Jean Charles EpinatChief Technological OfficerN/AN/AN/A
Dr. Philippe Duchateau Ph.D.Chief Scientific OfficerN/AN/A1963
Mr. Stephan Reynier M.Sc.Chief Regulatory & Pharmaceutical Compliance OfficerN/AN/A1969
Ms. Marie-Bleuenn TerrierGeneral Counsel & Secretary of the Board of DirectorsN/AN/A1982
Pascalyne WilsonDirector of CommunicationsN/AN/AN/A
Ms. Kyung Nam-WortmanExecutive VP & Chief Human Resources OfficerN/AN/A1970
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates. The company is developing ALLO-715 and ALLO-605 for the treatment of multiple myeloma; ALLO-501 to treat large B-cell lymphoma; ALLO-316, an allogeneic engineered CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin's lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics, Inc.; and joint research and collaboration, and investment agreement with AstraZeneca Holdings B.V., as well as with AstraZeneca Ireland Limited. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Corporate governance

Cellectis S.A.’s ISS governance QualityScore as of 1 May 2024 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder rights: 9; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.